Verona Pharma: Up on starting part 2 of pulmonary disease treatment trial

Verona Pharma

19/08/2020 11:23

** Shares of drug developer  VRP.L   VRNA.O  up 4.8% at
$8.59 premarket
    ** Company starts second part of a mid-stage trial assessing
its inhaler formulation of ensifentrine in patients with
moderate to severe chronic obstructive pulmonary disease
 urn:newsml:reuters.com:*:nGNX2zkh0p
    ** The formulation helped increase lung function in the
first part of the study; company had postponed the second part
due to COVID-19
    ** ~30 patients who took part in the first part of the trial
to participate in the second part, VRNA says
    ** Main goal of the second part of the study is improvement
in lung function after 7 days of treatment compared with placebo
    ** Stock up 42.6% this year, as of last close

 (Reporting by Trisha Roy in Bengaluru)
 ((Trisha.Roy@thomsonreuters.com; within U.S. +1 646 223 8780,
outside U.S. +91 80 6182 3635;))